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Abstract
Ridge Preservation Using Demineralized 
Bone Matrix Gel with Recombinant Human
Bone Morphogenetic Protein-2 After Tooth 
Extraction: A Randomized Controlled Clinical Trial
Yujin Kim, M.S.D
Department of Dentistry
The Graduate School, Yonsei University
Directed by Professor Kyoo-Sung Cho, D.D.S., M.S.D., PhD.
The aim of the present randomized controlled trial was to determine the 
safety and efficacy of injectable demineralized bone matrix (DBM) gel 
combined with recombinant human bone morphogenetic protein-2 (rhBMP-2) 
on alveolar ridge preservation after tooth extraction.
A total of 69 patients were randomly assigned to either a test group (n = 
35) or a control group (n = 34). In the test group, DBM, together with rhBMP-
2 (0.05 mg/mL; rhBMP-2/DBM) was transplanted into the extraction sockets. 
iv
The control group received DBM alone. The safety of rhBMP-2/DBM was 
evaluated by oral examination, serum chemistry, and hematologic examination. 
The radiographic changes in alveolar bone height and width were measured 
using computed tomography scans performed immediately after transplant and 
again 3 months thereafter.
Healing was uneventful in all subjects, with no anticipated adverse events 
and no clinically significant changes in the serum chemistry and hematologic 
findings. No meaningful immune response was found among the study groups. 
No significant difference was found in the radiographic changes of alveolar 
bone height and width (P > .05).
This new injectable biomaterial can be used easily and safely in clinical 
applications.
_______________________________________________________________
Keywords: rhBMP-2, Demineralized Bone Matrix, bone regeneration, human,
RCT
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I. Introduction
Demineralized bone matrix (DBM) is made from donated human bone 
from which the inorganic mineral has been removed, leaving behind the 
organic collagen matrix.1 During this process, a group of proteins becomes 
sequestered in the residual inorganic bone matrix; these proteins have been 
termed “bone morphogenetic proteins” (BMPs) by Urist.2 Owing to the 
osteogenetic characteristics of native BMPs, DBM has been classified as an 
2osteoinductive material,3 and it has been routinely used to promote bone 
regeneration, not only in orthopedic surgery, but also in dental implant 
surgery.4,5
However, controversy exists regarding the osteoinductive potential of 
DBM. Although it has been shown in animal studies that DBM implants 
placed in mid-diaphyseal defects and extraction sockets have failed to induce 
new bone formation,6,7 Landsberg et al8 found that DBM did promote bone 
formation in defects adjacent to dental implants. Even the results of meta-
analyses of previous clinical trials have been controversial. Reynolds et al9
reported a beneficial effect of DBM, and Laurell et al10 stated that its use 
might not be beneficial. This apparent lack of consistency in the ability of 
DBM to induce bone regeneration could be attributable to variations in the 
donor characteristics. A few studies have found that donor age, physiology, 
and pharmacologic status11,12 could be contributing factors to the variable 
osteoinductive capacity of DBM. Furthermore, the processing and sterilization 
protocols used have differed according to the bone bank used, which might 
have influenced the quality of the final product by affecting the DBM particle 
size,13 just as would the acid exposure times during the demineralization 
procedure. Therefore, the use of DBM in clinics, with the associated beneficial 
release of native BMPs, has been limited owing to their variable concentration 
3within, or inadequate recovery from bone. 
Recombinant technologies have been used to provide controlled 
concentrations of BMPs, resulting in the development of recombinant human 
BMP (rhBMP), which expresses osteoinductive properties.14-16 It has been 
shown that when rhBMP-2 is successfully loaded into inactive DBM, the 
addition of rhBMP-2 directly to inactive DBM provides consistent bone 
induction.17 Furthermore, a few other studies have found that DBM is a 
suitable carrier for rhBMP-2.18 The mechanism underlying these useful effects 
of DBM as a carrier for rhBMP-2 is not clear; however, it seems that the 
collagenous substrate that remains after hydrochloric acid extraction of the 
mineral fraction might provide a sustained pattern of release of the 
osteoinductive protein19 and serve as a scaffold for the proliferation and 
differentiation of osteoprogenitor cells.20 Moreover, the manufacture of DBM 
into a putty- or paste-type form provides easy handling without scattering, 
which might facilitate its retention in the grafted area.
To the best of our knowledge, no well-controlled, randomized clinical 
trials (RCTs) of the utility of DBM combined with rhBMP-2 and modified into 
an injectable gel form for ridge preservation after tooth extraction have been 
performed. Hence, the present study was designed to determine the effect of 
DBM combined with rhBMP-2 in injectable gel form (rhBMP-2/DBM) for 
4alveolar ridge preservation after exodontia. The aims of our RCT were to
assess the safety of rhBMP-2/DBM in human subjects and to evaluate the 
radiographic changes in the alveolar ridge after transplantation of either DBM 
alone or rhBMP-2/DBM gel into extraction sockets.
5II. Materials and methods
STUDY POPULATION AND DESIGN
The present single-blind, prospective, and parallel-arm RCT was 
conducted at 2 centers in the Republic of Korea from April 2011 to March 2013, 
and the study protocol was approved by the institutional review board at each of 
the 2 study centers (approval nos. 2-2010-0004, MD09019). The present study 
was conducted with the approval of the Korean Food and Drug Association. This 
clinical trial was registered at (http://cris.nih.go.kr/cris/index.jsp).
All patients aged 20 to 70 years, who required single tooth extraction 
in the anterior region and alveolar ridge preservation were candidates for the
present study. At the first visit, the patients were asked for their informed 
consent before enrollment in our study.
The inclusion criteria were systemically healthy subjects who required 
extraction of a single-rooted nonmolar tooth and residual extraction sockets 
with less than 50% bone loss in all dimensions. The exclusion criteria were the 
presence of severe periodontitis or acute infections at tooth extraction; 
pregnancy or planning to become pregnant within 1 year of the experiment; 
recent myocardial infarction or uncontrolled bleeding disorders; the presence 
6of mental illnesses or suspected mental illnesses; hypersensitivity to bone graft 
materials; and the presence of clinically significant or unstable systemic 
diseases affecting bone or soft tissue growth, or other renal, hepatic, endocrine,
hematologic, and autoimmune diseases.
Randomization was performed using a computer-generated 
randomization list. The randomization code was opened only at surgery (visit 
2), and the patients were randomly allocated to either the test group or the 
control group. The test group received rhBMP-2/DBM (Rafugen DBM Gel 
plus rhBMP-2, 0.05 mg/ml; Korea Bone Bank, Seoul, Korea). The control 
group received DBM alone into the extraction socket immediately after tooth 
removal.
PREPARATION OF rhBMP-2/DBM
After cleaning the cortical bones with distilled water and grinding 
them to a particle size of 0.5–1.0 mm, the lipid and fat were removed in 70% 
ethanol and 3% hydrogen peroxide for 2 hours. The bone specimens were 
decalcified in 0.6 N hydrochloric acid for 72 hours, lyophilized at –70ºC under 
vacuum conditions, and then stored at room temperature.
A 1-ml volume of Chinese hamster ovary cells expressing rhBMP-2 
7(0.05 mg/ml) was dispersed in 1 ml of DBM and stored at –70ºC overnight. It 
was then freeze dried at –70ºC under vacuum conditions. The freeze-dried 
powder was stored at 4ºC until clinical use.
To facilitate the handling and reliable delivery of DBM,21 porcine 
collagen gel and carboxy-methyl-cellulose (CMC) were applied to the matrix. 
Both DBM alone and rhBMP-2/DBM were mixed with 3% porcine collagen 
type I gel and 5.7% CMC. The mixture of DBM and porcine collagen gel 
(Rafugen DBM Gel, Korea Bone Bank, Seoul, Korea) and the mixture of 
rhBMP-2 coated DBM, collagen gel, and CMC (Rafugen BMP-2 DBM Gel,
Korea Bone Bank Co. Ltd.) were injectable using a syringe. Both types of gel 
were stored at 4ºC until clinical use.
8SURGICAL TREATMENT
After administration of local anesthesia, crestal and intrasulcular 
incisions were made to the adjacent teeth in all patients to expose the involved 
teeth and alveolar crest. Extractions were performed as atraumatically as 
possible. The teeth were sectioned if necessary to preserve all of the socket’s 
bony walls. The extraction sockets were thoroughly debrided to remove all 
soft tissue. The test material was delivered through a syringe and packed into 
the socket by 1 designated dentist at each of the 2 centers. It was passively 
packed after the careful bleeding control with gauze. A collagen membrane 
(Bio-Gide; Geistlich Biomaterials, Wolhusen, Switzerland) was tucked under 
the flaps and sutured over the materials using mattress suture technique.
Primary closure was obtained using periosteal releasing incisions, if possible; 
minor exposure was accepted (Fig 1).
The medication prescribed to all subjects included antibiotics (500 mg 
of amoxicillin 3 times daily for 5 days) and analgesics (200 mg of Ibuprofen 3
times daily for 5 days). The patients wore temporary prostheses after the 
surgery for esthetic reasons, taking care to avoid pressure on the wound area. 
The sutures were removed after 7 days, and the subjects were followed up 1 
and 3 months thereafter.
9SAFETY ASSESSMENT
The oral wounds at the treated sites were examined at each visit, 
including at baseline and days 2 and 14 and 1 and 3 months postoperatively, to 
monitor the occurrence of any of the commonly seen postoperative 
complications associated with the augmentation procedure (ie. pain, 
discomfort, swelling, fever, and wound dehiscence). Serum chemistry and 
hematology tests were performed at the screening and final visits, and the 
formation of antibodies to rhBMP-2 was evaluated using an enzyme-linked 
immunosorbent assay (Automatic Microplate reader, VERSAmax; Molecular 
Devices, Sunnyvale, CA).
RADIOGRAPHIC ANALYSIS
Computed tomography (CT; HiSpeed Advantage; GE Medical 
Systems, Milwaukee, WI; and SOMATOM Sensation 16; Siemens, Erlangen, 
Germany) was used to investigate the following parameters: alveolar bone 
height (1 measurement) and bone width (3 measurements at 1, 3, and 5 mm 
below the superior point of the lingual alveolar bone of the extraction sockets. 
These measurements were taken from the baseline CT scans (ie, within 4 days 
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after transplantation) and at 3 months thereafter. The data were processed in 
Digital Imaging and Communications in Medicine (DICOM) format, and the 
area of interest was reconstructed using the OnDemand 3-dimensional (3D) 
software (Cybermed, Seoul, Korea). The OnDemand “fusion” function, a 
visualization tool that uses a registration technique to combine and display the 
image data, was implemented to superimpose the original DICOM data of the 
2 CT scans. The 2 data sets were thus aligned and then manually checked to 
confirm a perfect match (Fig 2). Subsequently, the bone height and bone width 
responses (3-month value minus the baseline value for both; Fig 3) were 
calculated using the same reference points and lines.
STATISTICAL ANALYSIS
The major effects of the bone graft materials were assessed by 
comparing the alveolar bone height at baseline and 3 months after 
transplantation between the control and experimental groups. Furthermore, the 
minor effects of the bone graft materials, and changes in alveolar bone width 
at 1, 3, and 5 mm below the superior point of the lingual alveolar bone
immediately after ridge preservation and at 3 months after transplantation 
were compared between the control and experimental groups. 
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The mean ± standard deviation values of the test parameters was
calculated using Statistical Analysis System, version 9.1.3 (SAS Institute, Cary, 
NC, USA). For each parameter, the difference between the 2 groups was 
compared using the Wilcoxon rank sum test. The paired t test was used to 
determine the significance of the changes. P < .05 was considered statistically 
significant.
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III. Results
Patient flow through the study is shown in Figure 4. A total of 78
patients were initially screened, and 69 eligible patients were randomly 
allocated at surgery (visit 2) into the test group (n = 35) or the control group (n 
= 34). Six subjects were withdrawn or lost during follow-up period(Table 1). 
Although the radiologic data of another 6 patients were not of diagnostic 
quality, their clinical parameters were included in the safety assessment.
SAFETY ASSESSMENT
Healing was uneventful in all subjects, with no severe adverse events. 
No clinically significant changes were found in blood count, blood chemistry, 
or urinalysis results. The presence of antibodies to DBM alone and the 
rhBMP-2/DBM gel was found in 34 experimental patients and 32 control 
patients receiving bone graft material into extraction sockets. Of the 34 
patients receiving the rhBMP-2/DBM gel, 2 (5.88%) developed antibodies, 
compared to 0 of 32 (0%) in the control group; the difference was not
statistically significant (P = .4965; Table 2).
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RADIOGRAPHIC ANALYSIS
Representative cross-sectional CT images of both experimental groups 
are shown in Figure 5. The mean change in alveolar bone height, which was 
evaluated by comparing the CT scans taken immediately and 3 months after 
transplantation, was –1.50 ± 1.07 mm in the control group and –1.17 ± 
0.82 mm in the experimental group. Both groups exhibited a significant 
vertical height reduction from baseline to the final examination, and no 
statistically significant difference between the 2 groups (P > .05; Table 3).
Changes in the alveolar bone width were also measured to determine 
the minor effects of the bone grafts on the preservation of alveolar bone. At 
1 mm below the baseline, there was a –1.21 ± 1.31 mm change was seen in the 
bone width of the control group and –1.06 ± 1.26 mm in the experimental 
group. The corresponding values were –0.58 ± 0.68 and –0.43 ± 0.71 mm at 
3 mm below the baseline and –0.37 ± 0.61 and –0.23 ± 0.45 mm at 5 mm 
below the baseline. Therefore, both groups exhibited significant horizontal 
width reduction between the baseline and the final examination, with no 
statistically significant difference between the 2 groups (P > .05; Table 4).
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IV. Discussion
In the present study, the application of rhBMP-2 using injectable 
DBM gel into the extraction socket successfully preserved the volume of the 
alveolar ridge, and its clinical safety was well demonstrated. In addition, no 
adverse reactions to the graft material, including rhBMP-2 were observed.
The experimental model in the ridge preservation procedure after 
extraction is a well established study design and has been used in a number of 
studies.22 In the present study, the extraction sockets with buccal bone loss less 
than 50% were included, and Fiorellini et al23 included the sockets with more 
than 50% of buccal bone loss, termed the “postextraction buccal wall defect 
model”. Both study models are well established; however, the latter is more 
focused on the evaluation of efficacy than the former. The primary aim of the 
present study was to evaluate the local and systemic safety and the efficacy of 
the rhBMP-2/DBM gel. However, the evaluation of the efficacy of rhBMP-
2/DBM gel using the aforementioned buccal wall defect model could be 
investigated in future studies.
The rhBMP-2/DBM gel did not show a significant difference from the 
DBM alone in terms of alveolar bone width and height. We hypothesized that 
this phenomenon could be attributed to the relatively lower dosages of 
15
rhBMP-2 than those in the previous studies. 23,24 Controversies regarding the 
proper dosage of rhBMP-2 for maxillofacial application and uncertainty of 
possible adverse events from the higher dosage application still exist.25 In the 
present study, we used a lower dosage of rhBMP-2 than used in previous 
studies and maximum precaution was undertaken to ensure the safety of the 
materials. The results from the current study have shown that rhBMP-2/DBM 
gel and DBM alone were well tolerated both locally and systemically, with no 
adverse events, and we have shown that the resorption of the alveolar ridge 
was successfully prevented. Furthermore, the technical feasibility of device 
implantation was also achieved.
During the 3-month follow-up period, the patients experienced neither 
unexpected adverse events nor clinically significant changes in blood count, 
blood chemistry, or urinalysis results. Moreover, no significant immune 
response to rhBMP-2 was seen. Of the 34 patients receiving the rhBMP-
2/DBM gel, 2 (5.88%) developed antibodies. Antibody formation can have the 
potential to affect the safety or efficacy of the rhBMP-2. In some studies, no
difference was observed in the adverse event rates between antibody-positive 
patients and antibody negative patients, including adverse events.26 These 
findings are similar to those of previous studies using rhBMP-2/absorbable 
collagen sponge,27,28 suggesting that no specific toxicity is related to this study 
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device. However, several reports have been published of complications 
occurring after the application of rhBMP-2. Therefore, additional evaluation of 
changes in antibody titer should be conducted to monitor the long-term safety 
of this product.
The major limitation of the present study was the lack of a negative 
control group in which patients received no graft after extraction. However, 
the original purpose of our clinical trial was to compare the clinical and 
radiographic changes of the 2 transplanted materials within the extraction 
socket and to investigate their safety and efficacy using an injectable 
application. Therefore, it was beyond the scope of our study to ascertain the 
effect of the DBM applications compared with the outcomes for an untreated 
extraction socket. The results from the present study have substantially shown
that both materials are equally safe.
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V. Conclusion
The results from this randomized, controlled, multicenter clinical 
study have shown that the application of rhBMP-2/DBM or DBM gel is safe to 
use clinically for preservation of the alveolar ridge, and no difference in 
dimensional change was observed between the 2 groups.
18
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Legends
Figure 1. Clinical photographs of the surgical procedure.
(A) Residual root of the mandibular second premolar. (B) Extraction site after
atraumatic exodontia. (C) Placement of rhBMP-2/DBM into the socket (which 
was ultimately covered with a collagen membrane). (D) Primary coverage was 
achieved.
Figure 2. (A) Superimposition of the DICOM data of 2 CT images at (B), 
baseline and (C), 3 months after transplantation of maxillary left canine to 
determine whether any changes had occurred in the measurement parameters 
between the 2 points.
Figure 3. Radiographic, computed tomography (CT) measurements of the 
cross-sectional area, height, and width of alveolar bone at baseline(within 4 
days after transplantation or demineralized bone matrix (DBM) or 
recombinant human bone morphogenetic protein-2/DBM) and 3 months later. 
(A) First, point d was marked at the same point of the apex of the extraction 
socket on the representative CT scans taken at baseline and 3 months after 
transplantation. Second, line a’ connected points a and d, taking into 
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consideration the axis of the extraction socket. Third, points b and c were 
marked at the same distance from line a’. Fourth, line b’ connected points b 
and c. Fifth, line c’ was drawn perpendicular to line a’ from the most superior 
point of the buccal alveolar bone. Finally, the bone height was defined as the 
distance between point a and line c’. (B) First, line g was drawn perpendicular 
to line a’ from the most superior point of the lingual alveolar bone. Second, the 
alveolar bone width was measured at 1, 3, and 5 mm below line g.
Figure 4. Patient flow diagram.
Figure 5. Cross-sectional images of the grafted areas. CT scans made at 
baseline (A, C) and at 3 months after transplantation (B, D) for the DBM-only 
(maxillary right second premolar) and rhBMP-2/DBM (maxillary left canine) 
groups.
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Tables
TABLE 1. AGE AND SEX DISTRIBUTIONS IN BOTH GROUPS.
Item Classification Control group Experiment group All
Patients 34 35 69
Gender Male 19 15 34
Female 15 20 35
Age group Mean age(yr) 51.18 ± 10.14 50.37 ± 13.45
<50 yr 13 14 27
50−59 yr 15 12 27
>60 yr 6 9 15
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TABLE 2. EVALUATIONS OF THE SAFETY OF RHBMP-2/DBM
(IE, THE IMMUNE RESPONSE).
3 month Experimental group Control group P value*
Negative,n
(%)
Positive,n 
(%)
Negative,n
(%)
Positive,n
(%)
Baseline
Negative 31 (91.18) 2 (5.88) 29 (90.63) 0 (0.00) .4965
Positive 0 (0.00) 1 (2.94) 0 (0.00) 3 (9.38)
P < .05, *Fisher's exact test
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TABLE 3. RADIOGRAPHIC  EVALUATION OF CHANGES IN ALVEOLAR BONE HEIGHT IN THE BOTH GROUPS
Alveolar bone height
Baseline 3 months Height change P value
Mean ± SD Median Min, 
Max
Mean ± SD Median Min, 
Max
Mean ± SD Median Min, 
Max
Experimental group    
(n = 29)
20.98 ± 7.74 21.14 9.54
39.58
19.81 ± 7.73 19.03 7.29
37.17
–1.17 ± 0.82 –1.19 –2.71, 
0.00
.1844*
Control group      
(n = 30)
21.83 ± 6.89 22.12 11.79
35.75
20.32 ± 6.92 20.29 10.14
35.75
–1.50 ± 1.07 –1.41 –4.45, 
0.00
P < .05, *Wilcoxon rank sum test
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TABLE 4. RADIOGRAPHIC EVALUATION OF CHANGES IN ALVEOLAR BONE WIDTH IN BOTH GROUPS.
Alveolar bone 
width
Baseline 3 months Width change P value
Mean ±
SD
Median
Min,
Max
Mean ± 
SD
Median
Min,
Max
Mean ± 
SD
Median
Min,
Max
At
1 mm
Experimental 
group (n = 
29)
7.61 
±2.71
7.78 1.49
12.25
6.56 
±2.73
6.28 1.10
11.32
–1.06 
±1.26
–0.57 –5.58,
0.00
.4574*
Control group 
(n = 30)
8.39 
±2.00
8.29 5.50
13.01
7.18 
±2.04
7.51 4.29
12.76
–1.21 
±1.31
–0.94 –6.78,
0.00
At 
3 mm
Experimental 
group (n = 
29)
8.06 
±2.22
7.66 4.63 
12.30
7.63 
±2.22
6.96 4.49
11.38
–0.43 
±0.71
–0.16 –3.28,
0.00
.1758*
Control group
(n = 30)
8.57 
±2.44
8.36 4.97
14.16
7.98 
±2.34
7.68 4.30
14.04
–0.58 
±0.68
–0.34 –2.67,
0.00
At 
5 mm
Experimental 
group (n = 
29)
8.31 
±2.42
7.70 4.28
13.15
8.08 
±2.41
7.41 4.28
12.57
–0.23 
±0.45
0.00 –2.23,
0.00
.6939*
Control group 
(n = 30)
8.56 
±2.59
8.45 4.65
15.31
8.19 
±2.49
7.76 4.25
14.74
–0.37 
±0.61
0.00 –2.24,
0.00
P < .05, *Wilcoxon rank sum test. 
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국문요약
제 2 형 재조합 인간 골형성 단백질을 포함한
탈무기화 골 기질(demineralized bone matrix, DBM)을 이용한
치조제 보존술에 대한 무작위 배정 임상 연구
<지도교수 조 규 성>
연세대학교 대학원 치의학과
김   유   진
본 연구는 국내에서 생산된 재조합 인간 골형성 단백질-2 (recombinant 
human bone morphogenetic protein-2; rhBMP-2)이 함유된 탈무기화 골기질
골이식재 (Demineralized Bone Matrix; DBM)의 안정성과 골재생의 효과 및
치조골의 보존 효과를 평가하는 것을 목적으로 한다.
본 연구는 69 명의 환자들을 실험군과 대조군으로 무작위 선정 및
배정한 후 조작이 편리하게 주입식으로 만든 골이식재를 단근치 발치후
발치와에 이식하였다. 실험군에 배정된 35 명의 환자에게는 단근치 발치후
발치와에 재조합 인간 골형성 단백질-2 (rhBMP-2)이 함유된 탈무기화
골기질 골이식재 (DBM)를, 대조군에 배정된 34 명의 환자에게는 탈무기화
골기질 골이식재 (DBM)를 이식하였다. 3 개월 후 실험군과 대조군의
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치조골 보존 효과를 방사선학적으로 평가한 것을 바탕으로 하여 1) 통계적
분석을 시행하여 유효성을 평가하고, 2) 혈청화학 검사와 혈액학적 검사를
시행하고 rhBMP-2 단백질에 대한 항체생성여부를 확인하여 안정성을
평가하였다.
안정성 평가 결과 모든 군에서 특기할 만한 부작용은 없었다. 혈청화학
검사와 혈액학적 검사에서 임상적인 문제는 발견되지 않았으며, 항체 생성
부분에서도 의미 있는 결과를 보이지 않았다. 유효성 평가에서는
이식수술을 한 직후와 3 개월을 비교한 결과 골높이와 폭에서 통계적으로
유의성은 없었다 (P >.05).
이상의 연구를 통해, 새로 계발된 주입식 골이식재는 임상에서 쉽고
안전하게 사용될 수 있음을 확인할 수 있었다.
_____________________________________________________________________
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